Long-term Combination
healing on push enteroscopy repeated 4 months aft er starting vedolizumab. Th ere were no infectious complications.
Patient 3: a 67-year-old female with CVID and pancytopenia receiving IVIG and fi lgastrim, with profuse diarrhea. Serologic and genetic testing was negative for celiac disease, autoimmune enteropathy, and infection. Push enteroscopy showed scalloping in the duodenum and jejunum without ulcers, and biopsies showed increased intraepithelial lymphocytes and villous atrophy. Colonoscopy showed patchy villous atrophy in the terminal ileum and loss of vascular pattern in the colon, and biopsies showed mild active chronic infl ammation in the ileum and right colon. She was treated with budesonide and vedolizumab induction and maintenance without symptomatic improvement over 52 weeks of therapy. Th ere were no infectious complications.
CVID, an immune defi ciency disorder, is frequently associated with paradoxical autoimmune manifestations, including persistent diarrhea with gut infl ammation in up to 60% of patients. Th e associated gut histopathologic fi ndings are diverse and may include intra-epithelial lymphocyte infi ltrate, lymphoid aggregates, and crypt distortion ( 1, 2 ) . Th e infectious risks associated with conventional medical therapies for infl ammatory bowel disease (IBD) are of signifi cant concern in the context of patients with CVID. While the topical steroid enteric-coated budesonide can be used, toxicity limits use of conventional steroids. Treatment with tumor necrosis factor (TNF) inhibitors has been described and has been clinically eff ective; but may signifi cantly increase the risk of opportunistic infections and therefore was not used ( 3 ) .
Vedolizumab selectively blocks leukocyte traffi cking to the gut, and is approved for treatment of ulcerative colitis and Crohn' s disease ( 4 ) . Th e gut selective mechanism of action has not been associated with an increased risk of opportunistic infections, making this a potentially appealing medication to use in the setting of CVID; however, the safety and effi cacy in vedolizumab in this patient population has not been described. We report the use of vedolizumab in anti-TNF naive patients with CVID and gut infl ammation without infectious complications
